Single-arm oncology trials and the nature of external controls arms

被引:12
|
作者
Hashmi, Mustafa [1 ]
Rassen, Jeremy [2 ]
Schneeweiss, Sebastian [1 ,2 ,3 ]
机构
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA
[2] Aetion Inc, Boston, MA 02109 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
关键词
adaptive clinical trials; clinical trials; nonrandomized trials; oncology; real-world evidence; trial design; CELL LUNG-CANCER; COMPARATIVE EFFICACY; BEVACIZUMAB; NSCLC;
D O I
10.2217/cer-2021-0003
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: Single-arm trials with external control arms (ECAs) have gained popularity in oncology. ECAs may consist of primary data from previous trials, electronic health records (EHRs) or aggregate data from the literature. We sought to provide a description of how such studies achieve similarity of patients, comparability of data quality and outcome assessment. Materials & methods: In a stratified convenience sample of 15 studies, five used primary data from trials as ECAs, five used secondary data from EHRs and five used aggregate data from the literature. Data were collected from the published literature and public web resources, blinded to the eventual approval decision. Results: Studies using ECAs from primary data and EHR data displayed methods to achieve comparability of information, including matched baseline characteristics. Aggregate data from published studies did not attempt to match covariates. The EHR controls often showed calendar time overlap for collecting information while trial data were mostly historic. Outcome data were not consistently reported across studies. US FDA approval was only seen when primary data from trials or EHR data were used as the ECA, however no ECA in this sample directly contributed to approval. Discussion: In this nonsystematic review of ECAs for single-arm trials, the ECAs derived from primary data collected by other trials or EHRs show patterns of patient comparability, time overlap, and realistic methodological approaches to achieving balance between treatment arms. They are often submitted to regulators while literature-derived aggregate findings as ECA may serve as benchmarks for pipeline decisions.
引用
收藏
页码:1053 / 1066
页数:14
相关论文
共 50 条
  • [1] Informing single-arm clinical trials with external controls
    Ruthie Davi
    Nirosha Mahendraratnam
    Arnaub Chatterjee
    C. Jill Dawson
    Rachel Sherman
    [J]. Nature Reviews Drug Discovery, 2020, 19 : 821 - 822
  • [2] Informing single-arm clinical trials with external controls
    Davi, Ruthie
    Mahendraratnam, Nirosha
    Chatterjee, Arnaub
    Dawson, C. Jill
    Sherman, Rachel
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (12) : 821 - 822
  • [3] Enriching single-arm clinical trials with external controls: possibilities and pitfalls
    Lambert, Jerome
    Lengline, Etienne
    Porcher, Raphael
    Thiebaut, Rodolphe
    Zohar, Sarah
    Chevret, Sylvie
    [J]. BLOOD ADVANCES, 2023, 7 (19) : 5680 - 5690
  • [4] The Targeted Virtual Control Approach for Single-Arm Clinical Trials with External Controls
    Fang, Yixin
    Zhong, Sheng
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (04): : 802 - 811
  • [5] USE OF SINGLE-ARM TRIALS IN CADTH REVIEWS OF ONCOLOGY DRUGS
    Wu, S.
    Zhang, E.
    Zou, D.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
  • [6] USE OF SINGLE-ARM TRIALS IN NICE REVIEWS OF ONCOLOGY DRUGS
    Zou, D.
    Wu, S.
    Zhang, E.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S117 - S117
  • [7] Single-arm trials for domestic oncology drug approvals in China
    Zhang, Hong
    Liu, Sen
    Ge, Chenghao
    Liu, Xiaozhen
    Liu, Yang
    Yin, Chen
    Li, Yi
    An, Jing
    Yan, Zhongtian
    Chen, Xiaoyuan
    [J]. CANCER BIOLOGY & MEDICINE, 2023, 20 (11) : 799 - 805
  • [8] Adaptive designs for single-arm phase II trials in oncology
    Englert, Stefan
    Kieser, Meinhard
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (03) : 241 - 249
  • [9] Single-arm trials for domestic oncology drug approvals in China
    Hong Zhang
    Sen Liu
    Chenghao Ge
    Xiaozhen Liu
    Yang Liu
    Chen Yin
    Yi Li
    Jing An
    Zhongtian Yan
    Xiaoyuan Chen
    [J]. Cancer Biology & Medicine, 2023, (11) : 799 - 805
  • [10] Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls
    Gray, Christen
    Ralphs, Eleanor
    Fox, Matthew P.
    Lash, Timothy L.
    Liu, Geoffrey
    Kou, Tzuyung Doug
    Rivera, Donna R.
    Bosco, Jaclyn
    Braun, Kim Van Naarden
    Grimson, Fiona
    Layton, Deborah
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (05)